drugset / Trial / NCT03807245

Group B Streptococcus Vaccine in Healthy Females

NCT03807245

Phase 1 Completed 60 enrolled Minervax ApS Simbec Research · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase I, randomised, single centre, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine.

Timeline

Start
2019-01-09
Primary completion
2019-10-14
Completion
2020-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GBS-NN/NN2 Vaccine 25 ug Intramuscular
Subject GBS-NN/NN2 Vaccine 50 ug Intramuscular